| __timestamp | Geron Corporation | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20707000 | 79696000 |
| Thursday, January 1, 2015 | 17831000 | 93236000 |
| Friday, January 1, 2016 | 18047000 | 150842000 |
| Sunday, January 1, 2017 | 11033000 | 150643000 |
| Monday, January 1, 2018 | 13432000 | 150252000 |
| Tuesday, January 1, 2019 | 52072000 | 140804000 |
| Wednesday, January 1, 2020 | 51488000 | 34236000 |
| Friday, January 1, 2021 | 85727000 | 35672000 |
| Saturday, January 1, 2022 | 95518000 | 66607000 |
| Sunday, January 1, 2023 | 125046000 | 76363000 |
| Monday, January 1, 2024 | 79048000 |
Unveiling the hidden dimensions of data
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Halozyme Therapeutics, Inc. and Geron Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Halozyme consistently outspent Geron, peaking in 2016 with R&D expenses nearly doubling Geron's. However, Geron has shown a remarkable upward trend, increasing its R&D spending by over 500% from 2014 to 2023. This surge reflects Geron's strategic pivot towards more aggressive innovation. Meanwhile, Halozyme's R&D expenses have seen fluctuations, with a notable dip in 2020. As of 2023, Geron's R&D spending reached its highest, closing the gap with Halozyme. This dynamic shift highlights the competitive nature of the biotech industry, where strategic investments in innovation can redefine market positions.
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Strategic Focus on R&D Spending
GSK plc or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Intra-Cellular Therapies, Inc. and Geron Corporation
R&D Insights: How Summit Therapeutics Inc. and Halozyme Therapeutics, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Geron Corporation
Research and Development Investment: Halozyme Therapeutics, Inc. vs PTC Therapeutics, Inc.
Research and Development Investment: Halozyme Therapeutics, Inc. vs Veracyte, Inc.
Revenue Showdown: Halozyme Therapeutics, Inc. vs Geron Corporation
Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Amneal Pharmaceuticals, Inc. vs Geron Corporation
Research and Development Investment: Soleno Therapeutics, Inc. vs Geron Corporation
Comparing Innovation Spending: Geron Corporation and Viridian Therapeutics, Inc.